5 Key Takeaways

• 1

  Encelto is the first FDA-approved treatment for macular telangiectasia type 2 (MacTel), designed to slow disease progression.

• 2

  The treatment involves a surgical implant that delivers sustained levels of ciliary neurotrophic factor (CNTF) to the retina.

• 3

  Encelto has a favorable risk-benefit profile, with a low complication rate and effectiveness lasting at least 10 years.

• 4

  Patient education is crucial, as discussions about slowing vision loss can be challenging and require setting appropriate expectations.

• 5

  Clinical studies show Encelto slows photoreceptor loss and preserves retinal sensitivity, making it a significant advancement in MacTel care.